Reuters logo
BRIEF-Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome
September 29, 2017 / 11:15 AM / 2 months ago

BRIEF-Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome

Sept 29 (Reuters) - Zogenix Inc:

* Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome

* Zogenix Inc - ZX008 also demonstrated statistical significance in all key secondary endpoints

* Zogenix Inc - ‍primary endpoint was achieved

* Zogenix Inc - ‍expect top-line results from second pivotal phase 3 trial, study 1504, which is nearing full enrollment, in first half of 2018​

* Zogenix Inc - ‍ZX008 was generally well-tolerated in study

* Zogenix Inc - remain on track to submit applications for regulatory approvals in U.S. And Europe in second half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below